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BACKGROUND & AIMS: Budesonide is a high-potency, second-
generation corticosteroid designed tominimize systemic adverse
consequences of conventional corticosteroids. We performed 2
randomized, phase 3 trials to evaluate the ability of budesonide
rectal foam, formulated to optimize retention and provide uni-
form delivery of budesonide to the rectum and distal colon, to
induce remission in patients with ulcerative proctitis or ulcera-
tive proctosigmoiditis. METHODS: Two identically designed,
randomized, double-blind, placebo-controlled trials evaluated
the efﬁcacy of budesonide foam for induction of remission in
546 patients with mild to moderate ulcerative proctitis or ul-
cerative proctosigmoiditis who received budesonide foam 2
mg/25 mL twice daily for 2 weeks, then once daily for 4 weeks,
or placebo. RESULTS: Remission at week 6 occurred signiﬁ-
cantly more frequently among patients receiving budesonide
foam than placebo (Study 1: 38.3% vs 25.8%; P ¼ .0324; Study
2: 44.0% vs 22.4%; P < .0001). A signiﬁcantly greater per-
centage of patients receiving budesonide foam vs placebo ach-
ieved rectal bleeding resolution (Study 1: 46.6% vs 28.0%;
P ¼ .0022; Study 2: 50.0% vs 28.6%; P ¼ .0002) and endoscopic
improvement (Study 1: 55.6% vs 43.2%; P ¼ .0486; Study 2:
56.0% vs 36.7%; P ¼ .0013) at week 6. Most adverse events
occurred at similar frequencies between groups, although
events related to changes in cortisol values were reported more
frequently with budesonide foam. There were no cases of clin-
ically symptomatic adrenal insufﬁciency. CONCLUSIONS:
Budesonide rectal foam was well tolerated and more efﬁcacious
than placebo in inducing remission in patients with mild to
moderate ulcerative proctitis and ulcerative proctosigmoiditis.
ClinicalTrials.gov ID: NCT01008410 and NCT01008423.Abbreviations used in this paper: ACTH, adrenocorticotropic hormone;
AE, adverse event; UC, ulcerative colitis; UP, ulcerative proctitis; UPS,Keywords: Inﬂammatory Bowel Disease; Ulcerative Colitis;
Budesonide; Ulcerative Proctosigmoiditis.
lcerative proctitis (UP) and ulcerative procto-
ulcerative proctosigmoiditis.
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Open access under CC BY-NC-ND license.Usigmoiditis (UPS) are part of the spectrum of ul-
cerative colitis (UC), an idiopathic chronic inﬂammatory
disease of the colon that is believed to be immune-medi-
ated.1 Approximately 46% of patients with UC arediagnosed with UP or UPS.2,3 Clinical UC symptoms include
rectal bleeding, diarrhea, urgency, tenesmus, and abdominal
pain.1 Oral or rectal mesalamine is often administered as
ﬁrst-line therapy.4,5 Suppositories and liquid enemas are
recommended for the induction of remission in patients
with mild to moderate UP, and they can be administered
alone or in combination with oral mesalamine when mild to
moderate disease extends beyond the rectum.1,6,7 However,
these rectal therapies have several limitations, including
difﬁculty of administration, retention, and limited proximal
spread. For example, suppositories disperse no further than
the rectum, and while liquid enemas can spread to the
splenic ﬂexure, they are difﬁcult for patients to retain and
require patients to remain recumbent for a speciﬁed period
of time after administration.1,8,9
Although active UP and UPS can be treated effectively
with systemic corticosteroids,6,10–12 their use can result in
adverse effects, including mood and sleep changes, Cush-
ingoid appearance, weight gain, ﬂuid retention, acne, and
hirsutism; longer-term use of systemic steroids can lead to
more serious adverse effects, such as increased risk of in-
fections, decreased bone density, ocular complications (eg,
glaucoma, cataracts), and adrenal insufﬁciency.6,13 There
remains an unmet need for therapies that can target the
area of active inﬂammation and yet have fewer systemic
effects than conventional steroids.
High-potency, second-generation corticosteroids,
including budesonide and beclomethasone, can be adminis-
tered either rectally or orally to produce a topical anti-
inﬂammatory effect. Budesonide has nearly 90% ﬁrst-pass
hepatic metabolism, thus reducing the potential for
corticosteroid-related adverse events (AEs).13–15 A ran-
domized, double-blind, dose-ranging study of patients with
active UP or distal UC receiving budesonide enema demon-
strated efﬁcacy (ie, increased rate of remission vs placebo,
improved endoscopic inﬂammation and histology scores
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active comparator study of patients with active UP, UPS, or
left-sided UC, budesonide enema had a safety proﬁle similar
to that of mesalamine enema, although mesalamine enema
induced remission in a signiﬁcantly greater percentage of
patients compared with budesonide enema (77.2% vs
63.5%, respectively; P < .05).17 Beclomethasone foam and
enema were shown to have efﬁcacy and safety proﬁles
similar to those observed for mesalamine foam and enema in
patients with mild to moderate UP or UPS after 8 weeks.18
Budesonide foam is a new rectal formulation of
budesonide that optimizes drug retention and provides
uniform drug delivery to the rectum and distal colon, with
a maximal spread of up to 40 cm (mean, 25.4 cm).19
Budesonide foam had an efﬁcacy proﬁle comparable
with that of hydrocortisone foam for treatment of UP and
UPS, with no signiﬁcant impact on cortisol concentrations
or increased occurrence of corticosteroid-related AEs
when administered for up to 8 weeks.20 A majority of
patients with active UP or UPS preferred a steroid foam
formulation to a steroid enema formulation.21 To evaluate
the efﬁcacy and safety of budesonide foam relative to
placebo in patients with active, mild to moderate UP and
UPS, we conducted 2 identically designed, 6-week, double-
blind induction trials.Methods
Patients
Patients aged 18 years and older with active UP or UPS
extending at least 5 cm, but no further than 40 cm from the
anal verge, were eligible for enrollment. Patients had mild to
moderate disease, with a baseline Modiﬁed Mayo Disease
Activity Index score (hereafter referred to as “Mayo score”)
between 5 and 10, inclusive, with subscale ratings of 2 for
endoscopic appearance and rectal bleeding. The Mayo score is
the sum of 4 subscale scores: stool frequency, rectal bleeding,
endoscopic ﬁndings, and a physician’s global assessment.
Since publication of the original Mayo Disease Activity In-
dex,22 the endoscopy subscale was modiﬁed such that patients
with any degree of friability are classiﬁed as having a subscale
score of 2.
Exclusion criteria included evidence of Crohn’s disease or
indeterminate colitis, signiﬁcant comorbid condition, a posi-
tive stool test for bacterial pathogens (Clostridium difﬁcile
toxin, or ovum and parasites), and adrenal insufﬁciency,
deﬁned as a measurement of <18 mg/dL serum cortisol after
adrenocorticotropic hormone (ACTH) challenge. Medication
restrictions included use of systemic, oral, topical, or rectal
corticosteroids; laxatives; enemas; treatments for irritable
bowel syndrome (eg, alosetron, lubiprostone); anticoagu-
lants; rectal mesalamine therapies; oral mesalamine
therapies at dosages of >4.8 g/d; narcotics; antibiotics; and
antidiarrheal medications (eg, loperamide, bismuth
subsalicylate).
The protocol was approved by institutional review boards
and ethics committees. All patients provided written informed
consent. All authors had full access to the study data and
reviewed and approved the ﬁnal manuscript.Study Design
Two identically designed, phase 3, randomized, double-
blind, placebo-controlled, multicenter studies (Study 1
[ClinicalTrials.gov ID: NCT01008410] and Study 2
[ClinicalTrials.gov ID: NCT01008423]) were conducted in the
United States and Russia during November 2009 to March
2013 (Study 2) or to April 2013 (Study 1). Patients were
assigned to a treatment group via a randomization schedule,
stratiﬁed by study center, generated by an interactive voice
response system/interactive web response system. Patients
were randomized in a 1:1 allocation to receive budesonide
rectal foam 2 mg/25 mL or placebo twice daily for 2 weeks,
then once daily for 4 weeks. Concomitant use of oral mesal-
amine drugs at a stable dosage of up to 4.8 g/d was
permitted. Each study consisted of a screening phase
(completed within 7 days of randomization), a single-blind
run-in/stabilization phase of 4 to 7 days, a 6-week double-
blind treatment phase, and a 2-week follow-up phase
(Supplementary Figure 1). Via administration of a placebo,
the single-blind run-in/stabilization phase allowed patients
to practice and familiarize themselves with appropriate use of
the foam delivery device before the treatment phase of the
study. Patients were required to meet inclusion criteria after
the run-in/stabilization phase to continue in the study. A
colonoscopy was required for patients newly diagnosed or
without a conﬁrmed diagnosis of UC within 12 months of the
screening visit. Colonoscopy, if needed, was performed no
more than 10 days, and no less than 4 days, before random-
ization. If a colonoscopy was not required, patients were
scheduled for sigmoidoscopy 4 to 7 days before randomiza-
tion. Histology results from the colonoscopy were required
from patients with newly diagnosed UC, before randomiza-
tion, to conﬁrm active UP or UPS.Assessments
The primary efﬁcacy end point was the percentage of pa-
tients achieving remission at week 6 (deﬁned as an endoscopy
subscore1, rectal bleeding subscore of 0, and improvement or
no change from baseline in the stool frequency subscore of the
Mayo score). Scores ranged from 0 to 3 for each subscore of the
Mayo score (endoscopy subscore: 0 ¼ normal or inactive dis-
ease, 1¼mild disease, 2¼moderate disease, 3¼ severe disease;
rectal bleeding subscore: 0¼ no blood seen, 1¼ streaks of blood
with stool less than half the time, 2 ¼ obvious blood with stool
most of the time, 3 ¼ blood alone passed; stool frequency sub-
score: 0 ¼ normal number of stools per day for each individual
patient, 1 ¼ 1 to 2 stools more than normal, 2 ¼ 3 to 4 stools
more than normal, 3 ¼ 5 stools more than normal; physician’s
global assessment subscore: 0 ¼ normal, 1 ¼ mild disease, 2 ¼
moderate disease, 3 ¼ severe disease). Endoscopic disease
extent and activity were determined by local investigators.
Key secondary efﬁcacy end points included the percent-
age of patients achieving a Mayo rectal bleeding subscore
of 0 at week 6, the number of scheduled assessments (weeks
1, 2, 4, and 6) in which patients had a rectal bleeding sub-
score of 0, and the percentage of patients achieving a Mayo
endoscopy subscore of 0 or 1 at week 6. Safety assessments
included monitoring of AEs, clinical laboratory tests
(including morning cortisol concentrations and ACTH
challenge tests), and vital signs. For purposes of reporting
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having a serum cortisol of 18 mg/dL at 30 minutes post-
ACTH challenge.
Pharmacokinetic Analysis
Blood samples for budesonide pharmacokinetic assess-
ments were collected on multiple visits from patients in the
United States. The time of administration of the most recent
dose of study drug and the time of blood collection were
recorded. Plasma budesonide concentrations were determined
using a validated high-performance liquid chromatography/
dual mass spectrometry method. Plasma budesonide concen-
trations were summarized by descriptive statistics and
analyzed by population-based pharmacokinetic methods using
NONMEM version 7.2 (ICON plc, Hanover, MD). Statistical
comparisons of pharmacokinetic data were performed using
the extended rank-sum test.23
Statistical Analyses
All patients randomized to treatment were included in the
intention-to-treat population. The safety population included
patients in the intention-to-treat population who received 1
dose of the study drug. Baseline characteristics, clinical labo-
ratory values, and AEs were summarized descriptively. Differ-
ences in treatment arms for the primary efﬁcacy end point and
secondary efﬁcacy end points with percentages as outcomes
were analyzed using a logistic regression model after adjusting
for analysis center effect. Subgroup analyses of the primary end
point were conducted based on the data combined from the 2
studies, by the same method that was used to analyze the
primary end point. Secondary efﬁcacy outcomes with catego-
rized changes (eg, change from baseline in Mayo score) were
analyzed using an ordinal logistic regression test, adjusting for
analysis center effect. Analysis of change from baseline was
performed by ﬁtting ﬁxed effects linear models to the data.
Analyses of ordinal data (eg, the number of scheduled assess-
ments with rectal bleeding responder classiﬁcations) were
performed using the proportional odds model for ordinal
outcome (ie, PROC LOGISTIC in SAS/STAT 9.3 software; SAS
Institute Inc, Cary, NC), adjusting for country effect. Multiplicity
of the key secondary efﬁcacy outcomes was addressed by sta-
tistical testing of the end points in a hierarchical manner: the
percentage of patients achieving a Mayo rectal bleeding sub-
score of 0 at week 6, the number of scheduled assessments
(weeks 1, 2, 4, and 6) in which patients had a rectal bleeding
subscore of 0, and 3), and the percentage of patients achieving a
Mayo endoscopy subscore of 0 or 1 at week 6. Mean compliance
percentages were calculated using the following equation:% compliance ¼
ð100  ½no: of applicators dispensed 
no: of applicators returnedÞ
ðno: of applicators scheduled for use
per planned treatment regimenÞSample size estimates assumed remission rates of 40% and
23% for budesonide foam and placebo, respectively, for both
studies. Based on the assumed remission rates and a signiﬁ-
cance level of a ¼ .05, it was determined that 133 patients were
needed in each treatment arm for each study to test the pri-
mary efﬁcacy end point with a power of 85%.Results
Patient Disposition and Demographics
A total of 546 patients (budesonide foam, n ¼ 267;
placebo, n ¼ 279) were included in the intention-to-treat
population of the 2 studies (Supplementary Figure 2). In
Study 1, one patient was randomized to treatment with
placebo but received both placebo and budesonide foam
during the study; this patient was included in the placebo
group for all efﬁcacy analyses and in the budesonide foam
group for all safety analyses as prespeciﬁed in the statistical
analysis plan. In Study 2, one patient randomized to treat-
ment with budesonide foam received placebo and was
included in the budesonide foam group for all efﬁcacy and
safety analyses as prespeciﬁed in the statistical analysis
plan. The majority of patients in each treatment arm
(>80%) completed the studies.
Demographic and baseline characteristics were gener-
ally comparable across treatment groups for each study
(Table 1). Most (approximately 90%) patients in each
treatment group were white, >50% were female, and the
mean ages across groups were 41 to 44 years. At baseline,
the mean total Mayo score was 8 for patients in each
treatment group, and the mean number of daily normal
stools ranged between 1.3 and 1.4. At least 67% of patients
in each treatment arm of both studies had proctosigmoiditis
(disease extending up to approximately 40 cm from the anal
verge), and approximately 26% to 33% of patients had
proctitis (disease extending approximately 15 cm from the
anal verge). More than half of patients receiving budesonide
foam or placebo in the studies reported concomitant use of
mesalamine or related compounds at baseline.
Most (>80%) patients were exposed to study drug for
29 to 44 days, with a mean duration of 38.8 (SD, 9.9) days
and 39.1 (SD, 9.2) days, for budesonide foam and placebo,
respectively, for the combined studies. Overall compliance
was high and was comparable between the 2 treatment
groups overall (budesonide foam, 94.0% vs placebo, 97.1%),
during twice-daily dosing (through week 2; 94.4% vs 97.0%,
respectively) and once-daily dosing (week 3 to week 6;
94.3% vs 97.5%, respectively).Efﬁcacy
Remission at week 6 (primary efﬁcacy end point) was
achieved in a signiﬁcantly greater percentage of patients
receiving budesonide foam compared with placebo in Study
1 and Study 2 (Figure 1). A signiﬁcantly greater percentage
of patients treated with budesonide foam achieved the key
secondary outcome of a rectal bleeding subscore of 0 at
week 6 compared with placebo in both Study 1 (P ¼ .0022)
and Study 2 (P ¼ .0002; Figure 2A). The number of sched-
uled assessments (out of 4) in which patients had a rectal
bleeding subscore of 0 signiﬁcantly favored treatment with
budesonide foam (Study 1: P ¼ .0004; Study 2: P < .0001).
In Study 1, a greater percentage of patients receiving
budesonide foam compared with placebo achieved rectal
bleeding subscores of 0 at 2 (18.8% vs 13.6%, respectively),
3 (21.1% vs 10.6%), and 4 (6.0% vs 1.5%) assessments. In
Table 1.Demographic and Baseline Characteristics (Intention-to-Treat Population)
Parameter
Study 1a Study 2b
Budesonide foam
2 mg/25 mL (n ¼ 133)
Placebo
(n ¼ 132)
Budesonide foam
2 mg/25 mL (n ¼ 134)
Placebo
(n ¼ 147)
Age, y, mean (SD) 43.2 (13.9) 41.4 (13.2) 44.3 (13.5) 41.9 (13.3)
Sex, n (%)
Male 61 (45.9) 52 (39.4) 62 (46.3) 63 (42.9)
Female 72 (54.1) 80 (60.6) 72 (53.7) 84 (57.1)
Race, n (%)
White 115 (86.5) 123 (93.2) 119 (88.8) 135 (91.8)
Other 18 (13.5) 9 (6.8) 15 (11.2) 12 (8.2)
BMI, kg/m2, mean (SD) 26.7 (5.8) 26.8 (5.5) 25.7 (5.3) 25.4 (4.7)
Duration of disease, y, mean (SD) 4.5 (6.9) 5.0 (7.0) 5.4 (6.3) 3.8 (4.8)
Extent of disease, n (%)
Proctitisc 37 (27.8) 43 (32.6) 35 (26.1) 38 (25.9)
Proctosigmoiditisd 95 (71.4) 88 (66.7) 98 (73.1) 109 (74.1)
Missing 1 (0.8) 1 (0.8) 1 (0.7) 0
Baseline extent of disease, cm, mean (SD) 23.8 (10.2) 22.3 (10.0) 25.2 (10.9) 25.0 (10.1)
Baseline Mayo total score, mean (SD) 7.8 (1.2) 7.9 (1.3) 7.9 (1.3) 8.0 (1.2)
Severity of disease, n (%)
Mild (Mayo score 4–6) 15 (11.3) 22 (16.7) 13 (9.7) 12 (8.2)
Moderate (Mayo score 7–10) 118 (88.7) 110 (83.3) 119 (88.8) 135 (91.8)
Severe (Mayo score 11–12) 0 0 2 (1.5) 0
Baseline Mayo rectal bleeding subscore, n (%)
0 1 (0.8) 0 0 0
1 1 (0.8) 2 (1.5) 3 (2.2) 1 (0.7)
2 116 (87.2) 113 (85.6) 112 (83.6) 123 (83.7)
3 15 (11.3) 17 (12.9) 19 (14.2) 23 (15.6)
Baseline Mayo endoscopy subscore, n (%)
Normal or inactive 0 0 0 0
Mild 0 0 0 0
Moderate 120 (90.2) 120 (90.9) 117 (87.3) 134 (91.2)
Severe 13 (9.8) 12 (9.1) 17 (12.7) 13 (8.8)
Baseline Mayo bowel frequency subscore, n (%)
0 9 (6.8) 10 (7.6) 13 (9.7) 9 (6.1)
1 37 (27.8) 35 (26.5) 44 (32.8) 49 (33.3)
2 56 (42.1) 47 (35.6) 44 (32.8) 53 (36.1)
3 31 (23.3) 40 (30.3) 33 (24.6) 36 (24.5)
Baseline Mayo physician global assessment
subscore, n (%)
0 0 0 0 0
1 25 (18.8) 23 (17.4) 7 (5.2) 10 (6.8)
2 105 (78.9) 107 (81.1) 125 (93.3) 133 (90.5)
3 3 (2.3) 2 (1.5) 2 (1.5) 4 (2.7)
Normal no. of stools/d, mean (SD) 1.3 (0.6) 1.4 (0.7) 1.4 (0.8) 1.4 (0.6)
Baseline use of mesalamine, n (%) 78 (58.6) 79 (59.8) 69 (51.5) 75 (51.0)
Baseline use of corticosteroids, n (%) 1 (0.8) 0 1 (0.7) 0
Baseline use of immunosuppressants, n (%) 1 (0.8) 0 0 0
Baseline use of biologics, n (%) 0 0 0 0
BMI, body mass index.
aOne patient was randomized to treatment with placebo but received both placebo and budesonide foam during the study. This
patient was included in the placebo group for the efﬁcacy analyses and the budesonide foam group for the safety population
analyses.
bOne patient was randomized to treatment with budesonide foam but received placebo during the study; this patient is
included in the budesonide foam group for efﬁcacy and safety analyses.
cProctitis was deﬁned as disease limited to the rectum (up to approximately 15 cm).
dProctosigmoiditis was deﬁned as disease limited to the rectum and sigmoid colon (up to approximately 40 cm from the anal
verge).
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Figure 1. Patients achieving
remission atweek6 (primary
efﬁcacy measure). Remis-
sion deﬁned as endoscopy
score 1, rectal bleeding
score¼ 0, and improvement
or no change from baseline
in stool frequencysubscales
of the Mayo score.
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0 occurred in a greater percentage of patients receiving
budesonide foam compared with placebo at 3 assessments
(21.6% vs 7.5%, respectively) and 4 assessments (13.4% vs
2.0%).
A rectal bleeding subscore of 0 was achieved within 1
week in a signiﬁcantly greater percentage of patients
receiving budesonide foam compared with placebo (Study
1: P ¼ .0438; Study 2: P ¼ .0043). The percentage of pa-
tients with a rectal bleeding response to budesonide foam vs
placebo increased by the second week of twice-daily dosing,
continued to improve at week 4 (once-daily dosing), and
was maintained at week 6 (once-daily dosing; Figure 2B) in
both studies. In addition, a signiﬁcantly greater percentage
of patients receiving budesonide foam compared with pla-
cebo achieved an endoscopy subscore of 0 or 1 at week 6 in
both Study 1 (P ¼ .0486) and Study 2 (P ¼ .0013;
Figure 2C). A greater percentage of patients in the budeso-
nide foam group achieved improvement or no change from
baseline in the Mayo stool frequency score compared with
the placebo group in Study 1 (78.9% vs 68.9%, respectively;
P ¼ .07) and in Study 2 (79.9% vs 72.8%, respectively;
P ¼ .18), although these differences were not signiﬁcant.
When expressed according to the percentage of patients
with improvement from baseline in the Mayo stool fre-
quency score, rates for budesonide foam were numerically
greater than those for placebo at weeks 1, 2, 4, and 6 in both
Study 1 (week 1, 49.6% vs 36.4%, respectively; week 2,
57.1% vs 40.2%; week 4, 54.9% vs 43.9%; and week 6,
52.6% vs 41.7%) and Study 2 (week 1, 41.0% vs 34.7%,
respectively; week 2, 52.2% vs 45.6%; week 4, 56.7% vs
46.9%; and week 6, 53.0% vs 42.2%).
In the combined population, the primary efﬁcacy end
point of remission was achieved by a signiﬁcantly greater
percentage of patients receiving budesonide foam compared
with placebo (P < .0001; Figure 1). A signiﬁcantly greaterpercentage of patients treated with budesonide foam ach-
ieved a rectal bleeding subscore of 0 at week 6 compared
with placebo in the combined population (P < .0001;
Figure 2A). The number of scheduled assessments (out
of 4) in which patients had a rectal bleeding subscore
of 0 signiﬁcantly favored treatment with budesonide
(P < .0001). A rectal bleeding subscore of 0 was achieved
within 1 week in a signiﬁcantly greater percentage of pa-
tients in the combined population receiving budesonide
foam compared with placebo (P ¼ .0005; Figure 2B). A
signiﬁcantly greater percentage of patients receiving bude-
sonide foam compared with placebo achieved an endoscopy
subscore of 0 or 1 at week 6 in the combined studies
(P ¼ .0002; Figure 2C).
When the primary end point was examined according to
relevant demographic and baseline characteristics, budeso-
nide foam was superior to placebo for nearly all subgroups
examined (ie, age, sex, white race, mild or moderate disease
severity, established disease, smoking history, extent of
disease, baseline use of mesalamine, and country;
Supplementary Figure 3). For example, budesonide foam
was more efﬁcacious than placebo in patients with UP
(treatment difference ¼ 14.6%; P ¼ .0315), as well as in
those with UPS (treatment difference ¼ 18.2%; P ¼ .0002).
Similarly, the treatment effect for patients in the United
States (treatment difference ¼ 15.6%; P ¼ .0005) and
Russia (treatment difference ¼ 18.2%; P ¼ .008) favored
budesonide foam over placebo. Subgroups for which sta-
tistical signiﬁcance vs placebo was not achieved tended to
have a low number of patients (ie, nonwhite race, mild
disease severity, and newly diagnosed disease).
Safety
The majority of AEs associated with treatment with
budesonide foam were mild to moderate in intensity
(Table 2). The most common AEs reported during treatment
Figure2. Patients achieving
secondary efﬁcacy out-
come measures. (A) Mayo
rectal bleeding subscore ¼
0 at week 6. (B) Week in
which patients received a
Mayo rectal bleeding
subscore ¼ 0. (C) Mayo
endoscopy subscore 1 at
week6.BID, twicedaily;QD,
once daily.
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Table 2.Summary of Adverse Events (Combined Analysis)
Adverse event
Budesonide foam
2 mg/25 mL
(n ¼ 268)a
Placebo
(n ¼ 278)
Any AE, n (%) 123 (45.9) 101 (36.3)
Discontinuation due to AE 26 (9.7) 12 (4.3)
Serious AEs 5 (1.9) 3 (1.1)
Intensity of AE, n (%)b,c
Mild 88 (32.8) 57 (20.5)
Moderate 27 (10.1) 40 (14.4)
Severe 8 (3.0) 4 (1.4)
Most common AEs, n (%)d
Decreased blood cortisol
concentrations
46 (17.2) 6 (2.2)
Adrenal insufﬁciency 10 (3.7) 2 (0.7)
Headache 6 (2.2) 7 (2.5)
Nausea 6 (2.2) 2 (0.7)
Ulcerative proctitis 0 6 (2.2)
aOne patient in Study 1 was randomized to treatment with
placebo but received both placebo and budesonide foam
during the study. This patient was included in the placebo
group for the efﬁcacy analyses and the budesonide foam
group for the safety population analyses. In Study 2, 1 patient
was randomized to treatment with budesonide foam but
received placebo during the study; this patient was included
in the budesonide foam group for efﬁcacy and safety
analyses.
bPatients experiencing 1 AE were counted once and cate-
gorized by the most severe intensity AE.
cPercentage of patients in each analysis based on total
population of the treatment group.
dAEs reported in 2% of patients in either treatment group.
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concentrations, adrenal insufﬁciency, headache, and nausea;
UP was reported as an AE only in the placebo treatment arm
(Table 2).The incidence of serious AEs was similar between groups
(budesonide foam, n ¼ 5 [1.9%], vs placebo, n ¼ 3 [1.1%]).
Most serious AEs were not considered to be related to
treatment with budesonide foam (eg, hypersensitivity [food
allergy], arterial thrombosis limb, UC, abdominal pain) or
placebo (eg, ectopic pregnancy, anemia, UC). However, 1
serious AE (acute generalized exanthematous pustulosis)
was considered by the investigator to be related to treatment
with budesonide foam and resolved without sequelae;
the patient experiencing this event discontinued from the
study.
Mean morning cortisol concentrations remained within
normal levels after treatment with budesonide foam,
although a transient decrease in mean cortisol concentra-
tions was observed during twice-daily dosing, with a return
to baseline concentrations observed by week 6 (Figure 3).
Most of the patients treated with budesonide foam main-
tained normal total cortisol concentrations (>138 nmol/L)
throughout the study and had normal responses to an ACTH
challenge (Table 3). Normal total cortisol concentrations
were apparent in >96% of patients in both treatment
groups at baseline. During weeks 1 and 2 (twice-daily
dosing), 85.2% and 84.0% of patients receiving budesonide
foam maintained normal total cortisol concentrations.
During weeks 4 and 6 (once-daily dosing), 92.8% and
94.2% of patients maintained normal total cortisol con-
centrations. The percentage of patients receiving placebo
with normal total cortisol concentrations remained high
(>97%) and virtually unchanged during the 6-week dura-
tion of the study. Normal responses to ACTH challenge at
baseline (using the >18 mg/dL criterion) occurred in 98.1%
and 98.9% of patients receiving budesonide foam and pla-
cebo, respectively. At week 6, the percentage of patients
receiving budesonide foam or placebo with normal re-
sponses to ACTH challenge was 86.1% and 96.2%, respec-
tively. No patients with abnormal ACTH challenge resultsFigure 3.Mean morning
serum cortisol concentra-
tions. BID, twice daily; QD,
once daily.
Table 3.Total Cortisol Concentrations and Normal Response
to ACTH Challenge (Combined Analysis)
Parameter
Budesonide foam
2 mg/25 mL
(n ¼ 268)
Placebo
(n ¼ 278)
Total cortisol >5 mg/dL
(138 nmol/L),a n/Nb (%)
Baseline 259/268 (96.6) 275/278 (98.9)
Week 1 (bid) 224/263 (85.2) 264/269 (98.1)
Week 2 (bid) 216/257 (84.0) 263/266 (98.9)
Week 4 (qd) 218/235 (92.8) 243/249 (97.6)
Week 6 (qd) 211/224 (94.2) 234/241 (97.1)
Normal response to
ACTH challenge,c n/Nb (%)
Baseline 261/266 (98.1) 275/278 (98.9)
Week 6 186/216 (86.1) 226/235 (96.2)
bid, twice daily; qd, once daily.
aLower limit of normal.
bDenominator N is the number of patients with a value at each
given week during the study.
cDeﬁned as a measurement of >18 mg/dL serum cortisol after
ACTH challenge.
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of adrenal suppression. In addition, neither patients with
AEs of decreased blood cortisol nor adrenal insufﬁciency
reported any other AEs potentially indicative of adrenal
suppression.
Glucocorticoid-related AEs—such as moon face, striae
rubrae, ﬂushing, ﬂuid retention, mood changes, sleep
changes, insomnia, acne, and hirsutism—were infrequently
reported. Among budesonide foam–treated patients, 1 pa-
tient (0.4%) experienced insomnia, 1 patient experienced
sleep disorder, and 1 patient experienced acne.Pharmacokinetics
Low systemic exposure was observed in both studies, as
shown by the substantial number of post-randomization
plasma samples (39% in Study 1 and 27% in Study 2)
from budesonide-treated patients that had budesonide
concentrations below the limit of quantitation (0.03 ng/mL).
Mean plasma budesonide concentrations, in samples above
the limit of quantitation, were 0.37 ng/mL at week 1 (twice-
daily treatment phase), and 0.18 ng/mL at week 6 (once-
daily treatment phase) in Study 1; similar mean plasma
budesonide concentrations were observed in Study 2. These
plasma concentrations, along with the population-estimated
mean maximum plasma concentration value across the 2
studies (0.57 ng/mL) and the highest budesonide plasma
concentration observed in each of the studies (2.22 ng/mL
in Study 1 and 1.96 ng/mL in Study 2), further demonstrate
the low systemic exposure to budesonide. Budesonide sys-
temic exposure (estimated area under the plasma
concentration-time curve and maximum plasma concentra-
tion) did not correlate with decreased sensitivity to ACTH
challenge at week 6, and systemic exposure was not sta-
tistically different between patients with normal vsabnormal ACTH challenge results (mean maximum plasma
concentration, 0.53 ng/mL vs 0.79 ng/mL, respectively;
P ¼ .27). In total, these data suggest that budesonide foam
did not have clinically relevant effects on the hypothalamic-
pituitary-adrenal axis. In addition, systemic exposure was
not affected by disease severity.Discussion
In 2 identically designed, randomized, placebo-
controlled studies, treatment with budesonide foam
demonstrated signiﬁcant beneﬁt over placebo based on the
rate of remission at week 6 among patients with active mild
to moderate UP or UPS. Subgroup analyses of the combined
data showed a consistent beneﬁt for budesonide vs placebo
across a variety of subgroups, deﬁned by demographic and
baseline disease characteristics. Notably, budesonide foam
appeared to be efﬁcacious in patients with diagnosed UP
(disease extending approximately 15 cm from the anal
verge) and UPS (disease extending up to 40 cm from the
anal verge), and in patients with or without baseline
mesalamine use. Signiﬁcant treatment beneﬁts were also
observed in both studies for multiple prespeciﬁed second-
ary end points, including Mayo rectal bleeding subscore of
0 at week 6, rectal bleeding subscore of 0 at multiple
scheduled assessments, and endoscopic improvement
(Mayo endoscopy subscore of 0 or 1) at week 6. The stool
frequency component of the primary end point of remission
was deﬁned as improvement or no change from baseline.
Although there was no signiﬁcant difference between
groups in the Mayo stool frequency score, a budesonide
treatment effect on the stool frequency score component
would not necessarily be expected, given that between 34%
and 43% of patients with UP or UPS have normal stools or
constipation.24,25 When speciﬁcally examined, the percent-
age of patients receiving budesonide foam who reported
improvement in stool frequency score was numerically
greater than the percentage of patients receiving placebo at
all weeks across both studies. These ﬁndings are suggestive
of stool frequency improvements at the population level.
Although AEs related to changes in cortisol laboratory
values were reported in a greater percentage of patients
receiving budesonide foam compared with placebo, the
incidence of other AEs was similar in the budesonide and
placebo groups, and no clinically important safety signals
were identiﬁed.
The current results conﬁrm the ﬁndings of 2 other in-
duction studies with budesonide foam in patients with
active mild to moderate UP and UPS, which demonstrated
that budesonide foam was similarly effective to hydrocor-
tisone acetate enemas20 and budesonide enemas.21 When
taken together, the results of the 2 current trials and earlier
studies demonstrate that budesonide foam is an efﬁcacious
treatment for inducing remission in patients with mild to
moderate UP and UPS.
The design of the trials incorporated dose reduction with
a budesonide rectal foam (ie, twice-daily to once-daily
dosing) that is consistent with the dosing of steroids in
clinical practice. Clinical and endoscopic remission were
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daily dosing. The initial twice-daily dosing regimen
demonstrated rapid improvements in the rectal bleeding
component of the Mayo score, as evidenced by signiﬁcant
differences vs placebo as early as the ﬁrst week of treat-
ment. Overall, the largest incremental improvement in rectal
bleeding response to budesonide occurred within the ﬁrst 2
weeks, during twice-daily dosing, and was further improved
at week 4 and maintained at week 6, during once-daily
dosing. It should be noted, however, that these analyses
were not prespeciﬁed.
Although budesonide rectal foam exhibits high potency
at the local application site, it has low systemic bioavail-
ability due to rapid ﬁrst-pass metabolism; this proﬁle is
predicted to decrease the incidence of steroid-related
adverse effects as compared with rates for conventional
corticosteroids. Low systemic bioavailability was also
observed in the current study in patients with UP or UPS.
Mean plasma budesonide concentrations, as well as the
highest plasma concentrations observed in patients
treated with budesonide, were similar to or lower than
systemic exposures observed after administration of
budesonide extended-release tablets (budesonide with
multi-matrix system technology; Cosmo Pharmaceuticals
SpA, Lainate, Italy) in healthy individuals.26 The incidence
of AEs and serious AEs was generally similar in the
budesonide foam and placebo treatment groups. The
overall safety proﬁle of budesonide foam in the current
study was consistent with results reported in trials of
other budesonide formulations for patients with UC,
including budesonide enemas and oral budesonide multi-
matrix system technology.27–29
Reduction in plasma cortisol concentrations and abnor-
malities in adrenal responsiveness are known effects of
systemic corticosteroids and are a potential concern during
UC treatment.30 As a second-generation corticosteroid,
budesonide has been shown to cause less adrenal sup-
pression compared with equivalent doses of conventional
steroids, as measured by serum cortisol concentrations.31
The effects of budesonide rectal foam on the
hypothalamic-pituitary-adrenal axis in these studies were
evaluated by review of laboratory assessments, including
morning cortisol and ACTH challenge tests, and review of
AEs and vital signs. It appears that budesonide rectal foam,
at the dose and duration administered, had no clinical or
biochemical consequences regarding adrenal gland sup-
pression in most patients. Although morning cortisol values
were decreased in a small percentage of patients, no AEs
related to symptoms of adrenal insufﬁciency were reported
in these patients. This ﬁnding could be due to the minimal
reduction in serum cortisol values or to the direct phar-
macologic effects of circulating budesonide. The results of
ACTH stimulation testing further conﬁrmed that biochem-
ical adrenal suppression occurred in a small percentage of
patients (eg, 14% for budesonide group compared with 4%
in the placebo group at week 6). This suggests that plasma
levels of budesonide were adequate to attenuate adrenal
responsiveness to ACTH stimulation in only a small subset
of patients and that, overall, the drug has a low probabilityof causing biochemical adrenal suppression. These minimal
effects on the hypothalamic-pituitary-adrenal axis are in
contrast with results from studies of other corticosteroid
products for the treatment of UC.6,32,33
Compliance with the foam study medications was
high for patients in each treatment group (budesonide
94%, placebo 97%). These levels of compliance are
consistent with those reported in other studies that
compared rectal foams containing budesonide or mesal-
amine with various liquid enema formulations and in
which retention with rectal foams was better than reten-
tion with rectal liquid enemas.21,34 Rectal foams were
preferred to enemas by a large majority of patients, largely
due to convenience and ease of use.21 The high rates of
compliance observed in our studies demonstrated that
budesonide rectal foam can be used effectively by patients
with distal forms of UC.
In conclusion, budesonide rectal foam 2 mg twice daily
for 2 weeks and then once daily for 4 weeks was generally
well tolerated and was superior to placebo in inducing
remission in patients with active, mild to moderate UP and
UPS. The dosage form allows for targeted delivery to the
affected areas of the rectum/sigmoid colon in patients with
distal forms of UC and allows for reduction from a 2-week
phase of twice-daily dosing to a 4-week phase of once-
daily dosing, reducing the potential for systemic steroid-
related adverse effects. The safety proﬁle of budesonide
foam demonstrated in these studies is consistent with
worldwide experience of budesonide products.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Figure 1. Study design. aA colonoscopy was required for patients newly diagnosed or without a conﬁrmed
diagnosis of UC within 12 months of the screening visit. Colonoscopy, if needed, was performed no more than 10 days, and no
less than 4 days, before randomization. If a colonoscopy was not required, patients were scheduled for sigmoidoscopy 4 to 7
days before randomization. BID, twice daily; EOS, end of study; EOT, end of treatment; QD, once daily.
Supplementary Figure 2. Study disposition. SAE, serious adverse event.
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Supplementary Figure 3. Patients achieving remission at week 6 (primary efﬁcacy measure) by subgroup in the combined
study population. Remission deﬁned as endoscopy score 1, rectal bleeding score ¼ 0, and improvement or no change from
baseline in stool frequency subscales of the Mayo score. aIn Study 2, moderate severity of disease included 2 patients treated
with budesonide foam who had severe disease at baseline.
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